keyword
MENU ▼
Read by QxMD icon Read
search

Landmark trial

keyword
https://www.readbyqxmd.com/read/29341833/immune-modified-response-evaluation-criteria-in-solid-tumors-imrecist-refining-guidelines-to-assess-the-clinical-benefit-of-cancer-immunotherapy
#1
F Stephen Hodi, Marcus Ballinger, Benjamin Lyons, Jean-Charles Soria, Mizuki Nishino, Josep Tabernero, Thomas Powles, David Smith, Axel Hoos, Chris McKenna, Ulrich Beyer, Ina Rhee, Gregg Fine, Nathan Winslow, Daniel S Chen, Jedd D Wolchok
Purpose Treating solid tumors with cancer immunotherapy (CIT) can result in unconventional responses and overall survival (OS) benefits that are not adequately captured by Response Evaluation Criteria In Solid Tumors (RECIST) v1.1. We describe immune-modified RECIST (imRECIST) criteria, designed to better capture CIT responses. Patients and Methods Atezolizumab data from clinical trials in non-small-cell lung cancer, metastatic urothelial carcinoma, renal cell carcinoma, and melanoma were evaluated. Modifications to imRECIST versus RECIST v1...
January 17, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/29327180/chemotherapy-with-or-without-definitive-radiation-therapy-in-inoperable-pancreatic-cancer
#2
Jim Zhong, Jeffrey Switchenko, Madhusmita Behera, David Kooby, Shishir K Maithel, Mark W McDonald, Jolinta Y Lin, Richard J Cassidy, Bassel El-Rayes, Jerome Landry, Pretesh R Patel
BACKGROUND: The LAP07 randomized trial calls into question the role of radiation therapy (RT) in the modern treatment of locally advanced pancreatic cancer (LAPC). However, advances in chemotherapy and RT limit application of the LAP07 results to current clinical practice. Here we utilize the National Cancer Database (NCDB) to evaluate the effects of RT in patients receiving chemotherapy for LAPC. METHODS: Using the NCDB, patients with American Joint Committee on Cancer (AJCC) clinical stage T2-4, N0-1, M0 adenocarcinoma of the pancreas from 2004 to 2014 were analyzed...
January 11, 2018: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/29322619/randomized-comparison-of-novel-biodegradable-polymer-and-durable-polymer-coated-cobalt-chromium-sirolimus-eluting-stents-three-year-outcomes-of-the-i-love-it-2-trial
#3
Lei Song, Jing Li, Changdong Guan, Quanmin Jing, Shuzheng Lu, Lixia Yang, Kai Xu, Yuejin Yang, Bo Xu, Yaling Han
OBJECTIVES: We aimed to compare the long-term outcomes of the novel biodegradable polymer cobalt-chromium sirolimus-eluting stent (BP-SES) versus the durable polymer sirolimus-eluting stent (DP-SES) in the I-LOVE-IT2 trial. BACKGROUNDS: Comparisons of the long-term safety and efficiency of the BP-DES versus the DP-DES are limited. METHODS: A total of 2,737 patients eligible for coronary stenting were randomized to the BP-SES or DP-SES group at a 2:1 ratio...
January 11, 2018: Catheterization and Cardiovascular Interventions
https://www.readbyqxmd.com/read/29307509/two-years-postradiotherapy-biopsies-lessons-from-mrc-rt01-trial
#4
Antoine Kass-Iliyya, Gordana Jovic, Claire Murphy, Cyril Fisher, Isabel Syndikus, Chakiath Jose, Christopher D Scrase, John D Graham, David Nicol, Matthew R Sydes, David Dearnaley
BACKGROUND: The importance of 2-yr postradiotherapy prostate biopsy status remains uncertain. OBJECTIVE: To assess the value of 2 year post treatment biopsies in a randomised trial of radiotherapy dose escalation. DESIGN, SETTING, AND PARTICIPANTS: Between 1998 and 2001, 843 men with localised prostate cancer were randomised to receive either control-64Gy or escalated-74Gy conformal radiotherapy (CFRT) in the MRC RT01 trial in combination with 3-6-mo neoadjuvant androgen deprivation therapy...
January 4, 2018: European Urology
https://www.readbyqxmd.com/read/29306514/intermediate-endpoints-after-postprostatectomy-radiotherapy-5-year-distant-metastasis-to-predict-overall-survival
#5
William C Jackson, Krithika Suresh, Vasu Tumati, Steven G Allen, Robert T Dess, Simpa S Salami, Arvin George, Samuel D Kaffenberger, David C Miller, Jason W D Hearn, Shruti Jolly, Rohit Mehra, Brent K Hollenbeck, Ganesh S Palapattu, Matthew Schipper, Felix Y Feng, Todd M Morgan, Neil B Desai, Daniel E Spratt
BACKGROUND: Intermediate clinical endpoints (ICEs) prognostic for overall survival (OS) are needed for men receiving postprostatectomy radiation therapy (PORT) to improve clinical trial design. OBJECTIVE: To identify a potential ICE for men receiving PORT. DESIGN, SETTING, AND PARTICIPANTS: We performed an institutional review board-approved multi-institutional retrospective study of 566 men consecutively treated with PORT at tertiary care centers from 1986 to 2013...
January 3, 2018: European Urology
https://www.readbyqxmd.com/read/29301648/effect-of-increasing-stent-length-on-3-year-clinical-outcomes-in-women-undergoing-percutaneous-coronary-intervention-with-new-generation-drug-eluting-stents-patient-level-pooled-analysis-of-randomized-trials-from-the%C3%A2-win-des-initiative
#6
Jaya Chandrasekhar, Usman Baber, Samantha Sartori, Giulio G Stefanini, Michele Sarin, Birgit Vogel, Serdar Farhan, Edoardo Camenzind, Martin B Leon, Gregg W Stone, Patrick W Serruys, William Wijns, Philippe G Steg, Giora Weisz, Alaide Chieffo, Adnan Kastrati, Stephan Windecker, Marie-Claude Morice, Pieter C Smits, Clemens von Birgelen, Ghada W Mikhail, Dipti Itchhaporia, Laxmi Mehta, Hyo-Soo Kim, Marco Valgimigli, Raban V Jeger, Takeshi Kimura, Søren Galatius, David Kandzari, George Dangas, Roxana Mehran
OBJECTIVES: The aim of this study was to examine whether stent length per patient and stent length per lesion are negative markers for 3-year outcomes in women following percutaneous coronary intervention (PCI) with new-generation drug-eluting stents (DES). BACKGROUND: In the era of advanced stent technologies, whether stent length remains a correlate of adverse outcomes is unclear. METHODS: Women treated with new-generation DES in 14 randomized trials from the WIN-DES (Women in Innovation and Drug-Eluting Stents) pooled database were evaluated...
January 8, 2018: JACC. Cardiovascular Interventions
https://www.readbyqxmd.com/read/29300282/meta-analysis-of-surgeon-performed-central-line-placement-real-time-ultrasound-vs-landmark-technique
#7
Lori A Gurien, Martin L Blakely, Marie C Crandall, Cameron Schlegel, Mallikarjuna R Rettiganti, Marie E Saylors, Daniel J France, Shilo Anders, Sheila L Thomas, Melvin S Dassinger
BACKGROUND: Major health care agencies recommend real-time ultrasound (RTUS) guidance during insertion of percutaneous central venous catheters (CVC) based on studies in which CVCs were placed by non-surgeons. We conducted a meta-analysis to compare outcomes for surgeon-performed RTUS-guided CVC insertion versus traditional landmark technique. METHODS: A systematic review of the literature was performed identifying randomized controlled trials (RCT) and prospective "safety studies" of surgeon-performed CVC insertions comparing landmark to RTUS techniques...
January 4, 2018: Journal of Trauma and Acute Care Surgery
https://www.readbyqxmd.com/read/29297385/tailoring-nutrition-therapy-to-illness-and-recovery
#8
REVIEW
Paul E Wischmeyer
Without doubt, in medicine as in life, one size does not fit all. We do not administer the same drug or dose to every patient at all times, so why then would we live under the illusion that we should give the same nutrition at all times in the continuum of critical illness? We have long lived under the assumption that critical illness and trauma lead to a consistent early increase in metabolic/caloric need, the so-called "hypermetabolism" of critical illness. What if this is incorrect? Recent data indicate that early underfeeding of calories (trophic feeding) may have benefits and may require consideration in well-nourished patients...
December 28, 2017: Critical Care: the Official Journal of the Critical Care Forum
https://www.readbyqxmd.com/read/29283960/trauma-laparoscopy-from-1925-2017-publication-history-and-study-demographics-of-an-evolving-modality
#9
Lauren Coleman, Gareth Gilna, Dana Portenier, Edward Auyang, Uzer Khan, Daniel Grabo, Alison Wilson, Nova Szoka
The use of laparoscopy in trauma surgery remains a debated topic, despite having been discussed in the literature for decades. The publication history of trauma laparoscopy was reviewed to identify trends, analyze study demographics, and summarize key papers, with hopes to better inform future areas of research. A systematic search of PubMed and Cochrane libraries was performed for English-language literature involving trauma laparoscopy through August 2017. Year published, number of subjects, study design, mechanism, type of laparoscopy (screening, therapeutic, diagnostic), journal, and location of study were recorded...
December 28, 2017: Journal of Trauma and Acute Care Surgery
https://www.readbyqxmd.com/read/29279269/renin-angiotensin-aldosterone-system-raas-blockers-usage-among-type-ii-diabetes-mellitus-patients-a-retrospective-study
#10
Yen Ping Ng, Ganesh Pandian Balasubramanian, Yi Ping Heng, Meera Kalaiselvan, Yu Wen Teh, Kin Man Cheong, Muhammad Faiz Bin Abdul Hadi, Rosmaliza Bt Othman
AIMS: Recent data showed an alarming rise of new dialysis cases secondary to diabetic nephropathy despite the growing usage of RAAS blockers. Primary objective of this study is to explore the prevalence of RAAS blockers usage among type II diabetic patients, secondary objectives are to compare the prescribing pattern of RAAS blocker between primary and tertiary care center and to explore if the dose of RAAS blocker prescribed was at optimal dose as suggested by trials. MATERIALS AND METHODS: This is a retrospective study conducted at one public tertiary referral hospital and one public health clinic in Sungai Petani, Kedah, Malaysia...
December 21, 2017: Diabetes & Metabolic Syndrome
https://www.readbyqxmd.com/read/29261442/seven-month-prostate-specific-antigen-is-prognostic-in-metastatic-hormone-sensitive-prostate-cancer-treated-with-androgen-deprivation-with-or-without-docetaxel
#11
Lauren C Harshman, Yu-Hui Chen, Glenn Liu, Michael A Carducci, David Jarrard, Robert Dreicer, Noah Hahn, Jorge A Garcia, Maha Hussain, Daniel Shevrin, Mario Eisenberger, Manish Kohli, Elizabeth R Plimack, Matthew Cooney, Nicholas J Vogelzang, Joel Picus, Robert Dipaola, Christopher J Sweeney
Purpose We evaluated the relationship between prostate-specific antigen (PSA) and overall survival in the context of a prospectively randomized clinical trial comparing androgen-deprivation therapy (ADT) plus docetaxel with ADT alone for initial metastatic hormone-sensitive prostate cancer. Methods We performed a landmark survival analysis at 7 months using the E3805 Chemohormonal Therapy Versus Androgen Ablation Randomized Trial for Extensive Disease in Prostate Cancer (CHAARTED) database ( ClinicalTrials...
December 20, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/29239748/validation-of-an-alignment-method-using-motion-tracking-system-for-in-vitro-orientation-of-cadaveric-hip-joints-with-reduced-set-of-anatomical-landmarks
#12
Suzan Bsat, Ifaz Haider, Andrew Speirs, Paul Beaulé, Hanspeter Frei
Accurate in-vitro orientation of cadaveric hip joints is challenging due to limited available anatomical landmarks. Published hip joint in-vitro investigations commonly lack details on methods used to achieve reported orientations and the accuracy with which the desired orientation has been achieved. The aim of this study was to develop an accurate method for orienting hip joints with limited anatomical landmarks for in-vitro investigations, and to compare this method against orientation using guiding axes and by visual approximation...
November 25, 2017: Medical Engineering & Physics
https://www.readbyqxmd.com/read/29239515/rationale-and-design-of-transition-a-randomized-trial-of-pre-discharge-vs-post-discharge-initiation-of-sacubitril-valsartan
#13
Domingo Pascual-Figal, Rolf Wachter, Michele Senni, Jan Belohlavek, Adele Noè, David Carr, Dmytro Butylin
AIMS: The prognosis after hospitalization for acute decompensated heart failure (ADHF) remains poor, especially <30 days post-discharge. Evidence-based medications with prognostic impact administered at discharge improve survival and hospital readmission, but robust studies comparing pre-discharge with post-discharge initiation are rare. The PARADIGM-HF trial established sacubitril/valsartan as a new evidence-based therapy in patients with heart failure (HF) and reduced left ventricular ejection fraction (<40%) (rEF)...
December 14, 2017: ESC Heart Failure
https://www.readbyqxmd.com/read/29232249/clinical-trials-in-valvular-surgery-a-2018-update
#14
Bobby Yanagawa, Amine Mazine, Derrick Y Tam, Subodh Verma
PURPOSE OF REVIEW: There is a growing emphasis on the conduct of large-scale, multicenter randomized controlled trials (RCTs) to guide decision-making in cardiac surgery. Here we review recent landmark RCTs in cardiac valvular surgery. RECENT FINDINGS: RCTs are the gold-standard level of data in medicine. However, there are unique challenges of conducting large-scale surgical trials including funding, blinding, generalizability, nonstandardization of the surgical technique, crossover, among others...
December 11, 2017: Current Opinion in Cardiology
https://www.readbyqxmd.com/read/29230123/molecular-targets-in-non-small-cell-lung-cancer
#15
REVIEW
Ryan Griffin, Robert A Ramirez
Background: Lung cancer is the second most common cancer in the United States among men and women, and it is the most common cause of cancer-related death. Non-small cell lung cancer (NSCLC) represents approximately 85% of all lung cancer cases. Historically, patients with metastatic NSCLC received similar cytotoxic chemotherapy regimens. Genotyping studies have revealed genetic/molecular abnormalities in lung cancer. These driver mutations render a cancer dependent on that specific mutation's biochemical pathway for its growth and survival...
2017: Ochsner Journal
https://www.readbyqxmd.com/read/29228817/cangrelor-in-percutaneous-coronary-intervention-current-status-and-perspectives
#16
Dimitrios Alexopoulos, Christos Pappas, Danai Sfantou, John Lekakis
Cangrelor is an intravenously administered P2Y12 receptor antagonist with very fast, potent, and quickly reversible action. In the CHAMPION PHOENIX trial, cangrelor provided an improved anti-ischemic protection compared with clopidogrel, without increasing the risk of severe bleeding. Cangrelor is currently approved by drug regulating authorities for patients undergoing percutaneous coronary intervention (PCI) without prior treatment with a P2Y12 receptor antagonist and not receiving a glycoprotein IIb/IIIa inhibitor, while its use is endorsed with a class IIb recommendation by the European Society of Cardiology guidelines...
January 2018: Journal of Cardiovascular Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/29228640/comparison-of-primary-endpoints-between-publications-registries-and-protocols-of-phase-iii-cancer-clinical-trials
#17
Fei Liang, Xinmei Guo, Sheng Zhang, Hongxi Xue, Qiang Chen, Xichun Hu
Background: Decisions by leading journals to require trial registration and to make protocols of phase III randomized clinical trials (RCTs) publicly accessible were landmark events in clinical trial reporting. Materials and Methods: We identified phase III cancer RCTs published between 2013 and 2015 in New England Journal of Medicine (NEJM), The Lancet, The lancet Oncology, JAMA and Journal of Clinical Oncology (JCO). Results: We identified 345 reports of phase III RCTs of which 217 (62...
November 14, 2017: Oncotarget
https://www.readbyqxmd.com/read/29227818/neutrophil-lymphocyte-ratio-kinetics-in-patients-with-advanced-solid-tumours-on-phase-i-trials-of-pd-1-pd-l1-inhibitors
#18
Malaka Ameratunga, Maxime Chénard-Poirier, Irene Moreno Candilejo, Manuel Pedregal, Andrew Lui, David Dolling, Caterina Aversa, Alvaro Ingles Garces, Joo Ern Ang, Udai Banerji, Stan Kaye, Hui Gan, Bernard Doger, Victor Moreno, Johann de Bono, Juanita Lopez
BACKGROUND: Although the neutrophil-lymphocyte ratio (NLR) is prognostic in many oncological settings, its significance in the immunotherapy era is unknown. Mechanistically, PD-1/PD-L1 inhibitors may alter NLR. We sought to characterise NLR kinetics in patients with advanced solid tumours treated with PD-1/PD-L1 inhibitors. METHODS: Electronic records of patients treated with PD-1/PD-L1 inhibitors on phase I trials across three sites were reviewed. A high NLR (hNLR) was predefined as >5...
January 2018: European Journal of Cancer
https://www.readbyqxmd.com/read/29225740/glycemic-control-in-acute-illness
#19
REVIEW
Moritoki Egi, Nana Furushima, Shohei Makino, Satoshi Mizobuchi
Hyperglycemia is commonly observed in critical illness. A landmark large randomized controlled trial (RCT) reported that the incidence of hyperglycemia (blood glucose concentration > 108 mg/dl) was as high as 97.2% in critically ill patients. During the past two decades, a number of RCTs and several meta-analyses and network meta-analyses have been conducted to determine the optimal target for acute glycemic control. The results of those studies suggest that serum glucose concentration would be better to be maintained between 144 and 180 mg/dl...
December 2017: Korean Journal of Anesthesiology
https://www.readbyqxmd.com/read/29217001/long-term-safety-and-efficacy-of-platinum%C3%A2-chromium-everolimus-eluting-stents-in-coronary-artery-disease-5-year-results-from-the-platinum-trial
#20
Christopher R Kelly, Paul S Teirstein, Ian T Meredith, Bruno Farah, Christophe L Dubois, Robert L Feldman, Joseph Dens, Nobuhisa Hagiwara, Abram Rabinowitz, Didier Carrié, Vincent Pompili, Alain Bouchard, Shigeru Saito, Dominic J Allocco, Keith D Dawkins, Gregg W Stone
OBJECTIVES: The authors sought to evaluate the final 5-year safety and effectiveness of the platinum-chromium everolimus-eluting stent (PtCr-EES) in the randomized trial, as well as in 2 single-arm substudies that evaluated PtCr-EES in small vessels (diameter <2.5 mm; n = 94) and long lesions (24 to 34 mm; n = 102). BACKGROUND: In the multicenter, randomized PLATINUM (PLATINUM Clinical Trial to Assess the PROMUS Element Stent System for Treatment of De Novo Coronary Artery Lesions), the PtCr-EES was noninferior to the cobalt-chromium everolimus-eluting stent (CoCr-EES) at 1 year in 1,530 patients undergoing percutaneous coronary intervention...
December 11, 2017: JACC. Cardiovascular Interventions
keyword
keyword
11836
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"